RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

PURPOSE: This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223 in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) differentiated thyroid cancer. METHODS: RADTHYR is a multicenter, single-arm prospective Simon two-stage phase II trial (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Deandreis, Désirée, Maillard, Aline, Zerdoud, Slimane, Bournaud, Claire, Vija, Lavinia, Sajous, Christophe, Terroir, Marie, Leenhardt, Laurence, Schlumberger, Martin, Borget, Isabelle, Leboulleux, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426251/
https://www.ncbi.nlm.nih.gov/pubmed/33619600
http://dx.doi.org/10.1007/s00259-021-05229-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426251/
https://www.ncbi.nlm.nih.gov/pubmed/33619600
http://dx.doi.org/10.1007/s00259-021-05229-y

Ejemplares similares